RemeGen Co., Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China 2024-10-29 12:00
First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis 2024-08-06 17:00
RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment 2024-06-05 21:42
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 2024-06-04 09:38
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome 2024-05-21 17:35
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing 2024-05-10 16:26
RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome 2024-04-03 11:14
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 2024-03-11 10:36
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap 2024-02-02 21:30
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients 2024-01-12 18:17
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment 2023-12-28 15:45
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients 2023-12-18 20:56
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO) 2023-11-28 09:48
RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology 2023-11-15 16:35
Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis 2023-09-27 09:30
RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal 2023-07-25 16:00
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors 2023-07-10 10:24
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer 2023-06-05 21:26
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name 2023-06-05 21:17
RemeGen Celebrates World Intellectual Property Day 2023 2023-04-26 10:00
1 2